M&A Deal Summary |
|
|---|---|
| Date | 2017-07-06 |
| Target | SQi Diagnostics - Sqid-X System |
| Sector | Life Science |
| Buyer(s) | IRX Therapeutics |
| Sellers(s) | SQi Diagnostics |
| Deal Type | Divestiture |
SEARCH BY
IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor microenvironment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Data collected to date indicates that IRX-2 acts to restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells to recognize and destroy tumors.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Ontario M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
SQI Diagnostics, Inc. is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Ontario M&A | 1 of 1 |
| Country: Canada M&A | 1 of 1 |
| Year: 2017 M&A | 1 of 1 |
